30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Year in Review

2014 Revenue: NuVasive

4Q14 revenue: $204.3MM, +7% (Ex-U.S. +36%; U.S. Lumbar +4%, U.S. Cervical +5%)

  • Biologics +9%
  • Monitoring Service -4%

Precept posterior fixation surpassed $100MM in cumulative sales since launch


2014 revenue: $762.4MM, +11% (U.S. +8%; ex-U.S. $103MM, +43%, with Japan over $20MM)

  • Spine Surgery $590.4MM, +11% (U.S. Lumbar +7%, U.S. Cervical +3%)
  • Biologics $129.5MM, +12%
  • Monitoring Service $42.3MM, +8%

Growth driven by U.S. lumbar and biologics (particularly Osteocel Pro), continued strong ex-U.S. sales

Claims #3 global spine market share

Pushing into 70% range of hardware cases also using biologics platform

Integrated Global Alignment platform will include launch of the Reliant portfolio for posterior fixation

Other 2015 launches include CoRoent Anterior TLIF, CoRoent Oblique TLIF, Bendini 2, NUVAMap, Archon R, etc.